An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
← catalyst calendarNCT07222267 · readout in 1,138 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
86estimated
Sites
31
Countries
Australia, China, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-11 | actual | When the study began enrolling |
| Primary completion | 2029-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2037-01-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Advanced Solid Tumor
Interventions
- Drug: BG-75202
- Drug: CDK4 Inhibitor
- Drug: Estrogen Receptor Antagonist
- Drug: Aromatase Inhibitor
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants with Adverse Events (AEs)
measured From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 12 months
Part 1: Recommended Dose for Expansion (RDFE)
measured Estimated approximately 1 year
Part 2: Overall Response Rate (ORR)
measured Up to approximately 2 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed